OCUL Ocular Therapeutix, Inc.

11.03
+0.73  (7%)
Previous Close 10.30
Open 10.27
Price To book 4.66
Market Cap 320.18M
Shares 29,028,000
Volume 1,457,145
Short Ratio 5.24
Av. Daily Volume 888,289

SEC filingsSee all SEC filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 17816101
  2. 8-K - Current report 17816092
  3. DEF 14A - Other definitive proxy statements 17773069
  4. 8-K - Current report 17758083
  5. 8-K - Current report 17701768

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data released November 14, 2016. Primary endpoints met.
DEXTENZA
Post-surgical ocular inflammation and pain
Phase 3 trial did not meet primary endpoint - June 2016. Additional Phase 3 trial to be initiated pending data from a non-significant risk device study to be initiated in 2017.
DEXTENZA
Allergic conjunctivitis
Phase 3 initiated October 2016. Data due 1H 2018.
OTX-TP
Glaucoma and ocular hypertension
CRL July 25 2016 - due to manufacturing deficiencies. NDA resubmitted, PDUFA date July 19, 2017.
DEXTENZA
Ocular inflammation and pain following cataract surgery
Phase 2 complete. Assessing plans forward.
DEXTENZA
Dry Eye Disease

Latest News

  1. Ocular Therapeutix™ Presented Phase 3 Data for DEXTENZA™ at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
  2. Ocular Therapeutix™ Presents Preclinical Data on Pharmacokinetics, Efficacy and Tolerability of Sustained Release Intravitreal Tyrosine Kinase Inhibitor Hydrogel Depot (OTX-TKI) at the ARVO Annual Meeting
  3. Why Ocular Therapeutix Inc Stock Jumped Higher Today
  4. Betting on Adamis Pharmaceuticals and Ocular Therapeutix Ahead of FDA Decisions
  5. Today's Research Reports on Stocks to Watch: ImmunoGen and Ocular Therapeutix
  6. Ocular Therapeutix™ Presents Additional Phase 3 Data and Patient Reported Outcomes Results for DEXTENZA™ at the American Society of Cataract and Refractive Surgery (ASCRS) Symposium
  7. Edited Transcript of OCUL earnings conference call or presentation 5-May-17 12:30pm GMT
  8. Why Ocular Theraputix Inc. Got Hammered Today
  9. Ocular Therapeutix reports 1Q loss
  10. Investor Network: Ocular Therapeutix Inc to Host Earnings Call
  11. Ocular Therapeutix™ Reports First Quarter 2017 Financial Results
  12. Ocular Therapeutix™ to Present Data on Anterior and Posterior Segment Drug Product Candidates at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
  13. Ocular Therapeutix™ to Report First Quarter 2017 Financial Results
  14. ETFs with exposure to Ocular Therapeutix, Inc. : April 24, 2017
  15. Ocular Therapeutix™ to Present Additional Phase 3 Data and Patient Reported Outcomes Results for DEXTENZA™ at the American Society of Cataract and Refractive Surgery (ASCRS) Symposium
  16. Ocular Therapeutix™ Appoints George Migausky as Interim Chief Financial Officer
  17. ETFs with exposure to Ocular Therapeutix, Inc. : March 27, 2017
  18. Ocular Therapeutix, Inc. :OCUL-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017
  19. Positive Results Reported For Ocular Therapeutix Inc (OCUL) Dextenza Following Phase III Study